The Recall Desk
ModerateCPSC·78104·Announced 1978-12-12

Armour thyroid tablets safety caps replaced due to closure issues

Armour Pharmaceutical is replacing child-resistant caps on thyroid tablets because some adults could not properly close them, posing a poisoning risk to children.

What this means for you

Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.

Our severity reasoning: This is a voluntary precautionary action to correct a packaging defect that poses a theoretical risk of poisoning to children, with no reported injuries or illnesses.

Plain-English summary

Armour Pharmaceutical Company and the U.S. Consumer Product Safety Commission (CPSC) announced that Armour will replace the child-resistant caps on approximately 140,000 100-tablet bottles of prescription thyroid tablets. This action is a voluntary cap replacement program initiated by Armour following Commission testing, which indicated that some adults might be unable to properly reclose the safety feature of the package during home use.

The efficacy and safety of the thyroid tablets themselves are not in question, and the source text explicitly states that no recall of the medication is involved. The cap replacement is required to comply with regulations under the Poison Prevention Packaging Act, which mandates that at least 90% of adults tested be able to both open and properly close packages to protect young children from accidental ingestion. Armour has stopped distribution of the affected product and is replacing caps on current inventory in its warehouses.

Consumers are not instructed to return the product, as the issue pertains to the packaging of inventory held in warehouses. Armour plans to continue its safety packaging program to meet quality standards and ensure compliance with CPSC regulations.

The recalled product

Product
Armour Pharmaceutical thyroid tablets

Distribution

Distributed nationwide across the United States.